2021 SSAT Debate: Selective Approach to Resection of the Superior Mesenteric Artery in Pancreatic Cancer vs Superior Mesenteric Artery Encasement Is Not an Absolute Contraindication for Surgery in Pancreatic Cancer

J Gastrointest Surg. 2022 Mar;26(3):523-531. doi: 10.1007/s11605-021-05237-1. Epub 2022 Jan 20.

Abstract

This manuscript summarizes an excellent debate from the 2021 SSAT/Pancreas Club symposium on arterial resection in pancreas cancer. Two world-recognized experts, Professor Ugo Boggi from Pisa, IT, and Dr. Mark Truty from the Mayo Clinic in Rochester, MN, offered their views on the role of arterial resection in locally advanced pancreas ductal adenocarcinoma. Both speakers have extensive experience pushing the technical envelope with extended vascular resection in pancreatectomy. However, both highlight important concepts of resectability extending well beyond technique: namely, patient global physiology, tumor biology, and response to chemotherapy. The debate was spirited, and this subsequent review is an excellent look at the status quo. N. J. Zyromski, MD, Indianpolis, IN, November, 2021.

MeSH terms

  • Contraindications
  • Humans
  • Mesenteric Artery, Superior* / pathology
  • Mesenteric Artery, Superior* / surgery
  • Pancreatectomy
  • Pancreatic Neoplasms* / pathology
  • Pancreatic Neoplasms* / surgery